Haploidentical hematopoietic stem cell transplant with umbilical cord-derived multipotent mesenchymal cell infusion for the treatment of high-risk acute leukemia in children

References

• Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065–3073.
   PubMed Web of Science ®Google Scholar
• Wang HX, Yan HM, Duan LN, et al. Haploidentical hematopoietic stem cell transplantation in children hematologic malignancies with G-CSF mobilized marrow grafts without T cell depletion: a single center report of 45 cases. Pediatr Hematol Oncol 2009;26:19–128.
   Web of Science ®Google Scholar
• Wang HX, Yan HM, Liu J, et al. Haploidentical hematopoietic stem cell transplantation for non-Hodgkin's lymphoma with bone marrow involvement. Leuk Lymphoma 2009;50:1488–1493.
   PubMed Web of Science ®Google Scholar
• Wang HX, Yan HM, Wang ZD, et al. Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: a single center report of 29 cases. Leuk Lymphoma 2012;53:654–659.
   PubMed Web of Science ®Google Scholar
• Marks DI, Khattry N, Cummins M, et al. Haploidentical stem cell transplantation for children with acute leukemia. Br J Haematol 2006;134:196–201.
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010;16:S57–S63.
   PubMedGoogle Scholar
• Palma J, Salas L, Carrión F, et al. Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatr Blood Cancer 2012;59:895–901.
   PubMed Web of Science ®Google Scholar
• Dvorak CC, Gilman AL, Horn B, et al. Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose. Bone Marrow Transplant 2013;48:508–513.
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Lee JH, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011;118:2609–2617.
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013;19:117–122.
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013;121:849–857.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733–1738.
   PubMed Web of Science ®Google Scholar
• Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007;110:2764–2767.
   PubMed Web of Science ®Google Scholar
• Silla L, Valim V, Amorin B, et al. A safety and feasibility study with platelet lysate expanded bone marrow mesenchymal stromal cells for the treatment of acute graft-versus-host disease in Brazil. Leuk Lymphoma 2014;55:1203–1205.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease:a phase II study. Lancet 2008;371:1579–1586.
   PubMed Web of Science ®Google Scholar
• Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010;16:838–847.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Maziarz RT, Kebriaer P. MSCs in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17(1 Suppl.): S21–S29.
   PubMed Web of Science ®Google Scholar
• Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008;22:593–599.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Campioni D, Lanza F, et al. Cotransplantation of mesenchymal cells and a higher relapse rate: a role for HLA-G molecules? Leukemia 2008;22:2273.
   Google Scholar
• da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204–2213.
   PubMed Web of Science ®Google Scholar
• Jin HJ, Bae YK, Kim M, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 2013;14:17986–18001.
   PubMed Web of Science ®Google Scholar
• Via AG, Frizziero A, Oliva F. Biological properties of mesenchymal stem cells from different sources. Muscles Ligaments Tendons J 2012;2:154–162.
   PubMedGoogle Scholar
• Wang H, Wang Z, Zheng X, et al. Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia-a single-center experience. Cytotherapy 2013;15:1118–1125.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.
   PubMed Web of Science ®Google Scholar
• Goldman FD, Rumelhart SL, DeAlacron P, et al. Poor outcome in children with refractory/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors. Bone Marrow Transplant 2000;25:943–948.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009;15: 257–265.
   PubMed Web of Science ®Google Scholar
• Eyrich M, Leiler C, Lang P, et al. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34 + peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors. Bone Marrow Transplant 2007;32:379–390.
   Web of Science ®Google Scholar
• Palma J, Salas L, Carrión F, et al. Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatr Blood Cancer 2012;59:895–901.
   PubMed Web of Science ®Google Scholar
• Leung W, Campana D, Yang J, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011;118:223–230.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5: 309–313.
   PubMed Web of Science ®Google Scholar
• Bacher U, Asenova S, Badbaran A, et al. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. Clin Exp Med 2010;10:205–208.
   PubMed Web of Science ®Google Scholar
• Ding L, Zhu H, Yang Y, et al. Functional mesenchymal stem cells remain present in bone marrow microenvironment of patients with leukemia post-allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 2014;55:1635–1644.
   PubMed Web of Science ®Google Scholar
• Detante O, Moisan A, Dimastromatteo J, et al. Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplant 2009;18:1369–1379.
   PubMed Web of Science ®Google Scholar
• Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007;110:2764–2767.
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Ball LM, Cometa AM, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011;46:200–207.
   PubMed Web of Science ®Google Scholar
• Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 2011;20: 1679–1685.
   PubMed Web of Science ®Google Scholar
• Karlsson H, Samarasinghe S, Ball LM, et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008;112:532–541.
   PubMed Web of Science ®Google Scholar
• Huurman VA, Kalpoe JS, van de Linde P, et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006;29:842–847.
   PubMed Web of Science ®Google Scholar
• Schaenman JM, Shashidhar S, Rhee C, et al. Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Biol Blood Marrow Transplant 2011;17:693–702.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013;11:171
   PubMed Web of Science ®Google Scholar
• Wu KH, Sheu JN, Wu HP, et al. Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Transplantation 2013;95:773–777.
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Laranjeira P, Mendes S, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther 2013;4:125–132.
   PubMed Web of Science ®Google Scholar
• Raicevic G, Najar M, Stamatopoulos B, et al. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol 2011;270:207–216.
   PubMed Web of Science ®Google Scholar
• Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754–2759.
   PubMed Web of Science ®Google Scholar